Phase
Condition
Sarcopenia
Polymyositis (Inflammatory Muscle Disease)
Neuropathy
Treatment
Ravulizumab
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receivingravulizumab treatment in the frames of NDP in Poland.
Patients willing to participate in the study and signed Informed Consent Form (ICF).
Vaccination against N. meningitidis
Exclusion
Exclusion Criteria:
Those who plan to participate in gMG clinical trial on/after the date of firstravulizumab infusion through NDP.
Cognitive incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.
Study Design
Study Description
Connect with a study center
Research Site
Bydgoszcz,
PolandActive - Recruiting
Research Site
Bydgoszcz 3102014,
PolandSite Not Available
Research Site
Gdansk,
PolandActive - Recruiting
Research Site
Gdansk 3099434,
PolandSite Not Available
Research Site
Katowice,
PolandSite Not Available
Research Site
Katowice 3096472,
PolandSite Not Available
Research Site
Krakow,
PolandActive - Recruiting
Research Site
Krakow 3094802,
PolandSite Not Available
Research Site
Lodz,
PolandActive - Recruiting
Research Site
Lodz 3093133,
PolandSite Not Available
Research Site
Lublin,
PolandActive - Recruiting
Research Site
Lublin 765876,
PolandSite Not Available
Research Site
Poznan,
PolandSite Not Available
Research Site
Poznan 3088171,
PolandSite Not Available
Research Site
Szczecin,
PolandSite Not Available
Research Site
Szczecin 3083829,
PolandSite Not Available
Research Site
Warsaw,
PolandActive - Recruiting
Research Site
Warsaw 756135,
PolandSite Not Available
Research Site
Wroclaw,
PolandActive - Recruiting
Research Site
Wroclaw 3081368,
PolandSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.